Congress to Clinic: A Post-ESMO Breast Cancer 2021 Update on Immune-Based Therapies in TNBC

Join us for this interactive, live Webinar featuring global expert perspectives on immune-based therapies for triple-negative breast cancer (TNBC). Hear the latest data on immune checkpoint inhibitors, antibody-drug conjugates, and other immune-based strategies for managing TNBC. This webinar incorporates relevant data from the ESMO Breast Cancer Virtual Congress 2021 and offers participants an opportunity for their questions to be answered by the experts.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

  • Welcome and Introduction
  • Immune Checkpoint Inhibitors in the Management of Metastatic TNBC
  • Antibody-Drug Conjugates Targeting Cell Surface Receptors and Other Immune-Based Approaches
  • Summary
  • Audience Q&A

Faculty

Faculty
Nadia Harbeck, MD, PhD

Professor
Head, Breast Center
University of Munich (LMU)
Munich, Germany

Faculty
Ian E. Krop, MD, PhD

Associate Professor of Medicine
Harvard Medical School
Associate Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts
USA

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners to integrate currently available and emerging immune checkpoint inhibitor–based therapies for treatment of triple-negative breast cancer.

Target Audience
This program is intended for global physicians and other healthcare professionals who care for patients with triple-negative breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan individualized first-line treatment with immune checkpoint inhibitor–based therapy for individual patients with locally advanced or metastatic triple-negative breast cancer
  • Apply clinical evidence and expert recommendations using antibody–drug conjugates for patients with progressive triple-negative breast cancer after 1 or more previous lines of therapy
  • Manage specific treatment-related complications associated with the use of immune-based therapies and combinations in patients with breast cancer
  • Appraise ongoing clinical trials assessing new immune-based approaches for appropriate patients with no biomarkers or those with HER2-low or HER3-high triple-negative breast cancer
  • Evaluate recently presented data as part of ESMO Breast 2021

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.